TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female outpatients aged 16 to 50 years (inclusive).~2. House dust mite-induced allergic asthma with or without perennial allergic rhinitis for at least 1 year.~3. Sensitised to D. pteronyssinus and D.farinae (positive skin prick test (SPT) with wheal diameter ≥ 4 mm and specific IgE level ≥ 0.70 kU/L~4. Patients treated with inhaled corticosteroids (ICS) before the screening visit at a dose ≥ 200 µg and \< 1,000 µg equivalent budesonide/day.~Exclusion Criteria:~1. Mild intermittent asthma needed to be treated only with β2-agonist (GINA level 1).~2. Severe asthma needed to be treated with inhaled corticosteroids with a dose ≥ 1,000 µg/day equivalent budesonide.~3. FEV1 \< 70% of predicted value at Visit 1.~4. Co-sensitisation to other inhalant allergens than dust mites leading to clinically relevant allergic asthma and proven by a positive skin prick test with wheal diameter ≥ 4 mm and serum specific IgE ≥ 0.70 KU/L .~5. Patients with a past or current disease, which as judged by the investigator, may affect the patient's participation in or the outcome of the study. These diseases include, but are not limited to, past or current cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, immunological disease and endocrine disease.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 360 active patients with house dust mites related asthma with or without allergic rhinitis
- 2 (Type: PLACEBO_COMPARATOR): 180 patients in the placebo group with house -dust mites related asthma with or without allergic rhinitis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Follicular Lymphoma (FL)~* Confirmed diagnosis of Follicular lymphoma~* 18 years or above~* Verbal and written information about the study~Exclusion Criteria:~* No previous treatment for Follicular Lymphoma~* Clinical suspicion that the Follicular Lymphoma has transformed to aggressive lymphoma~* Several diseases such as malignancies etc.~* Screening laboratory values~* Current participation in any other interventional clinical study~* Breast feeding women or pregnant women~* Women of childbearing potential not willing to use adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Comparator 1 (Type: ACTIVE_COMPARATOR): Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 500mg
- Active Comparator 2 (Type: ACTIVE_COMPARATOR): Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 1000mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Additive Effects of Pravastatin and Valsartan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertension and low-density lipoprotein cholesterol levels \>100~Exclusion Criteria:~* Overt liver disease Chronic renal failure Hypothyroidism Myopathy Uncontrolled diabetes Severe hypertension

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- pravastatin (Type: ACTIVE_COMPARATOR): None
- valsartan (Type: ACTIVE_COMPARATOR): None
- pravastatin combined with valsartan (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients need to be administered Varenicline(Champix) in order to be enrolled in the surveillance.~Exclusion Criteria:~* Patients not administered Varenicline(Champix).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: None): Patients taking Varenicline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing High-flow Nasal Oxygen With Standard Management for Conscious Sedation During Endoscopic Retrograde Cholangiopancreatography in Prone Position

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. patients who will undergo endoscopic retrograde cholangiopancreatography under conscious sedation~Exclusion Criteria:~* 1. dementia or cognitive dysfunction~* 2. altered mental status~* 3. intubated patients or tracheostomy~* 4. pregnancy~* 5. recent history of nasal bleeding~* 6. illiteracy or foreigner

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard oxygenation(nasal cannula) (Type: NO_INTERVENTION): stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula
- high-flow humidified oxygen-delivery system(OptiFlow THRIVE) (Type: EXPERIMENTAL): Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluoride Retention in the Mouth of Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Good general health as evidenced by medical history~* Good oral health as evidenced by a clinical oral exam~* Having at least 20 teeth in the mouth, being at least 4 (natural or crowned) teeth in all four quadrants of the mouth~* Having salivary flow rate ranging from normal to hyposalivation according to direct flow rate determination methods~* Agreement to adhere to the study protocol~Exclusion Criteria:~* Unable to understand and/or follow study instructions~* Active periodontitis~* Oral pain~* In need of urgent dental care

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Fluoride mouthwash alone, then Calcium mouthwash before a fluoride mouthwash (Type: EXPERIMENTAL): Participants with normal to dry mouth will first test a Fluoride mouthwash containing 226 ppm of fluoride, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours. After a washout period of at least 3 days, they will then test a Calcium mouthwash (150 milimolars of calcium) immediately before the Fluoride mouthwash, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours.
- Calcium mouthwash before a fluoride mouthwash, then Fluoride mouthwash alone (Type: EXPERIMENTAL): Participants with normal to dry mouth will first test a Calcium mouthwash (150 milimolars of calcium) immediately before a Fluoride mouthwash containing 226 ppm of fluoride, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours. After a washout period of at least 3 days, they will then test the Fluoride mouthwash alone, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. SARS-CoV-2 positive~2. Age \>17 years and \< 80 years~3. P/F \< 250 mmHg~4. Bilateral pneumonia (infiltrates/interstitial)~5. CRP \>10mg/dL (or \>100mg/L)~6. Alternatively to 4-5-6 criteria a diagnosis of ARDS according to the Berlin definition (Ranieri M, et al. JAMA 2012)~Exclusion Criteria:~* Heart failure as predominant cause of acute respiratory failure~* Decompensated liver cirrhosis~* Cancer~* Organ transplantation~* HIV+~* dialysis~* long-term oxygen therapy, home mechanical ventilation~* Idiopathic pulmonary fibrosis~* Progressive neuromuscular disorders (e.g. Duchenne, Pompe, ALS)~* Dementia or decompensated psychiatric diseases~* immunosuppressive treatments~* Chronic use of corticosteroids~* Use of Tocilizumab~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Exposed to Methylprednisolone (Type: None): Consecutive SARS-CoV-2 positive patients with severe acute respiratory syndrome treated with methylprednisolone (MP) at low prolonged dose, fulfilling inclusion and exclusion criteria.
- Non-exposed to Methylprednisolone (Type: None): Concurrent patients fulfilling the same inclusion and exclusion criteria, never treated with steroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Cessation Intervention: Effectiveness in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke at least 10 cigarettes per day for the previous 6 months - Expired CO \> 9 ppm - Motivated to quit smoking - Able to read and write English - Willing to complete required study assessments, Aurora participating clinic patient~Exclusion Criteria:~* Uncontrolled hypertension (systolic \>180mm Hg or diastolic \>110mm Hg) - History of bipolar disorder or psychosis - Myocardial infarction or other serious cardiac problem in the previous 4 weeks - History of diagnosed anorexia and/or bulimia - Diagnosis of Alcohol Dependence in the previous 6 months by participant self-report or drinking 6 or more drinks on six or more days a week - History of seizure and/or serious head injury involving loss of consciousness - Use of contraindicated medications (MAO inhibitors, bupropion, lithium, anticonvulsants, antipsychotics) - Currently pregnant or breast-feeding - Unwilling to use effective contraception during the treatment phase - More than one participant from the same household - Allergic reactions to 3 or more classes of drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patch (Type: ACTIVE_COMPARATOR): None
- nicotine lozenge (Type: ACTIVE_COMPARATOR): None
- bupropion (Type: ACTIVE_COMPARATOR): None
- patch + lozenge (Type: ACTIVE_COMPARATOR): None
- buproion + lozenge (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥18 years and undergoing elective primary, unilateral Total Knee Arthroplasty (TKA)~* Women of non-childbearing potential~Exclusion Criteria:~* High risk for clinically significant bleeding~* Prior deep vein thrombosis~* Body weight above 135 kg~* Creatinine clearance below 60 ml/min~* Recent (\<6 months) myocardial infarction or ischemic stroke~* Contraindication listed in the local label of the comparator treatments~* Requirement for full dose anticoagulation or dual antiplatelet therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enoxaparin (Type: ACTIVE_COMPARATOR): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days until venography was performed.
- Apixaban (Type: ACTIVE_COMPARATOR): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received apixaban for at least 10 days until venography was performed.
- BAY1213790 0.3 mg/kg (post-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once post-surgery.
- BAY1213790 0.6 mg/kg (post-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.6 mg BAY1213790 once post-surgery.
- BAY1213790 1.2 mg/kg (post-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.2 mg BAY1213790 once post-surgery.
- BAY1213790 1.8 mg/kg (post-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once post-surgery.
- BAY1213790 0.3 mg/kg (pre-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once pre-surgery.
- BAY1213790 1.8 mg/kg (pre-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once pre-surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD~* 10 pack-year or greater history of cigarette smoking~* Post-bronchodilator FEV1/FVC of \<0.7~* Predicted FEV1 of 70% of normal or less~* Modified Medical Research Council (mMRC) dyspnea score of 2 or greater~Exclusion Criteria:~* Women who are pregnant, lactating, or planning to become pregnant~* Respiratory disorders other than COPD, including a current diagnosis of asthma~* Clinically significant non-respiratory diseases or abnormalities that are not adequate controlled~* Significant allergy or hypersensitivity to anticholinergics, beta-agonist, or the excipients of magnesium stereate or lactose used in the inhaler delivery device~* Hospitalization for COPD or pneumonia within 12 weeks prior to screening~* Lung volume reduction surgery within 12 weeks prior to screening~* Abnormal and clinically significant ECG findings at screening~* Clinically significant laboratory findings at screening~* Use of systemic corticosteroids, antibiotics for respiratory tract infections, strong cytochrome P450 3A4 inhibitors, high dose inhaled steroids (\>1000mcg fluticasone propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short- and long-acting inhaled beta2-agonists, ipratropium, inhaled sodium cromoglycate or nedocromil sodium, or investigational medicines for defined time periods prior to the screening visit~* Use of long-term oxygen therapy (12 hours or greater per day)~* Regular use of nebulized treatment with short-acting bronchodilators~* Participation in the acute phase of a pulmonary rehabilitation program~* A know or suspected history of alcohol or drug abuse~* Affiliation with the investigational site~* Previous use of GSK573719 or GW642444 alone or in combination, including the combination of fluticasone furoate and GW64244

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK573719/GW642444 (Type: EXPERIMENTAL): 62.5/25mcg
- GSK573719 (Type: EXPERIMENTAL): 62.5mcg
- GW642444 (Type: EXPERIMENTAL): 25mcg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* admission to henry ford hospital after March 1, 2012~* status post transcatheter aortic valve replacement via transfemoral catheter approach, with or without minor intra or post procedure events (GI bleeds, minor access bleeds, afib, etc)~Exclusion Criteria:~* Occurrence of major events including stroke, pacemaker placement, other CV repair or surgery required, etc)~* procedure via appropriate other than femoral access (transapical, transcaval)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Post procedure routine PT and or OT (Type: None): Routine PT and or OT
- Post Procedure PT and OT pathway (Type: None): Post procedure day zero nursing mobilization; post procedure day one PT and OT assessment and intervention, daily PT and OT intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Events Based On Statin Initiation In The Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ≥ 1 fill for atorvastatin or simvastatin (not including combination therapy) between 01 July 2006 and 30 November 2008~* Age ≥ 65 years as of the year of index date~* Continuous enrollment with medical and pharmacy benefits during the analytic period~Exclusion Criteria:~* 1 or more fills for a statin or other dyslipidemia medication in the 12-month pre-index period~* A pharmacy fill for clopidogrel or nitrates (except concomitant hydralazine) in the 12-month pre-index period~* Patients with evidence of a cardiovascular event in the 12-month pre-index period.~* Patients who received both atorvastatin and simvastatin on the index date~* Patients with unknown gender or region~* Patients who received dyslipidemia medications other than the index drug within 1 months (30 days) following the index date

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin Initiators (Type: None): None
- Simvastatin Initiators (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject aged \>=10 and \<26 years at the time of enrollment.~* Healthy subject as determined by medical history, physical examination, and judgment of the investigator.~* Negative urine pregnancy test for all female subjects.~* Subjects who have not received, or who have received no more than 1 prior dose within the past 4 years, of a vaccine containing 1 or more ACWY serogroup~Exclusion Criteria:~* Previous vaccination with any meningococcal serogroup B or purely polysaccharide (nonconjugate) meningococcal vaccine.~* Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.~* A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.~* Significant neurological disorder or history of seizure (excluding simple febrile seizure).~* Current chronic use of systemic antibiotics.~* Received any investigational vaccines, drugs, or devices within 28 days before administration of the first study vaccination.~* Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (ACWY Naive subjects, MenABCWY/Saline) (Type: EXPERIMENTAL): ACWY Naive subjects, MenABCWY/Saline
- Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM) (Type: EXPERIMENTAL): ACWY Naive subjects, rLP2086/MenACWY-CRM
- Group 3 (ACWY Experienced subjects, MenABCWY/Saline) (Type: EXPERIMENTAL): ACWY Experienced subjects, MenABCWY/Saline
- Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM) (Type: EXPERIMENTAL): ACWY Experienced subjects, rLP2086/MenACWY-CRM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete